what this is, and what it is not
About this CJC-1295 digest
A late-desk reading of the published literature — and a plain statement of what the word 'pharmacy' in the name does and does not mean.
What this project is
Pharmacy CJC-1295 is an after-hours reading of the peer-reviewed CJC-1295 literature — the record worked through the way a features desk works a story, not the way a counter fills an order. No clinic stands behind the type and no clinician writes it; the site gives no medical advice and makes, stocks, and sells nothing. Its work is a reading of published science, every figure carried back to its source.
The approach is simple: read the published record straight, lead with what was measured, attribute every number to its study, and mark plainly where the evidence stops. CJC-1295's literature is unusually narrative — a multi-day half-life, a preserved-pulsatility result, an albumin-bioconjugate design story, a discontinued Phase 2 program, a perennial DAC-versus-no-DAC confusion. We read it as the after-hours feature it deserves to be, not as a dashboard of selling points.
What 'pharmacy' means here
The word "pharmacy" in this site's name is editorial framing, not a claim about services. It signals the register we read the literature in — a who-studies-it, what-the-pharmacology-shows reading room — not a dispensary, a counter, or a prescribing service.
To be unambiguous: nothing is dispensed, prescribed, compounded, or sold here. There is no pharmacist on staff, no clinical team, and no inventory. CJC-1295 is an unapproved research chemical with no approved human indication anywhere [9], and this site exists to document its research record, not to facilitate access to it.
How we handle the evidence
We separate strength of evidence carefully. The human pharmacokinetics — the multi-day GH and IGF-1 elevation, the 5.8-8.1 day half-life — come from controlled Phase 1 studies and are reported as such [2]. The synergy rationale for the ipamorelin pairing rests on replicated mechanism studies [7]. Claims that lack controlled human support — body-composition outcomes, optimal dosing, long-term safety — are named as gaps, not dressed up as findings [9].
Where registries disagree on a molecular detail (the exact formula and mass of CJC-1295 are listed differently across CAS and PubChem), we flag the disagreement rather than pick a side silently. The point is a reader who leaves knowing what is established, what is plausible, and what is simply unknown.